Spinal Metastases
Conditions
Brief summary
The investigators are prospectively validating a prognostic clinical tool that uses a patient's modified Bauer grade, ambulatory status, and pre-operative serum albumin to predict survival, post-treatment morbidity, and functional outcomes in patients with metastatic disease involving the spine.
Detailed description
Recently, the investigators proposed a clinical prediction score that used a patient's modified Bauer grade, ambulatory status, and pre-operative serum albumin as a means to predict long-term survival following spine surgery for metastatic disease. This prognostic utility was developed using one-year mortality as the sole outcome measure. While the scoring system demonstrated many of the necessary attributes of a useful prediction tool, including simplicity, ease of use and clinical utility, it has yet to be validated prospectively and its capacity to predict other peri-operative outcomes, including physical and mental function following intervention, pain relief and the risk of complications, remain incompletely explored. To further evaluate the utility of this prognostic score, the investigators propose a series of three integrated experiments that will prospectively determine its capacity to accurately inform clinical decision making and recommendations for surgery for patients with metastatic spinal disease.
Interventions
None listed
Sponsors
Brigham and Women's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years of age 2. Confirmed diagnosis of cancer with metastatic spread to the mobile spine or sacrum 3. Able to consent for themselves at the time of the intake evaluation 4. Speaks English
Exclusion criteria
5. Primary bone tumors or leukemia 6. Metastases to other visceral or skeletal locations, without involvement of the spine or sacrum 7. History of prior spine surgery for metastatic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival | Up to 3 years | Mortality is documented using date of death in medical record |
| EuroQuol 5-Dimension (EQ5D) profile | Up to 3 years | Assessment of state of health and physical/mental function |
| Short-Form (SF)-12 | Up to 3 years | Assessment of state of health and physical/mental function |
| Visual Analog Scale (VAS) for pain | Up to 3 years | Assessment of current level of pain |
| Patient-Reported Outcomes Measurement Information System (PROMIS) | Up to 3 years | Assessment of global health |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post-treatment morbidity and readmissions | Up to 3 years | Post treatment complications and readmissions documented in medical record |
Countries
United States
Outcome results
None listed